ALEXANDRIA, Va., Oct. 8 -- United States Patent no. 12,435,123, issued on Oct. 7, was assigned to FATE THERAPEUTICS INC. (San Diego).
"Immunotherapies using enhanced iPSC derived effector cells" was invented by Bahram Valamehr (San Diego), Ryan Bjordahl (San Diego) and Tom Tong Lee (San Diego).
According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof compri...